Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Inflammopharmacology is Scopus-indexed (Q1, CiteScore 8.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Springer Science and Business Media Deutschland GmbH.
Checked against the index lists dated .
ISSN 0925-4692Verify ISSN ↗1568-5608Verify ISSN ↗
Publisher: Springer Science and Business Media Deutschland GmbH
Cost to publish: About US$4,990 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 31 / 278 | 89th | Q1 |
| Pharmacology | 50 / 328 | 84th | Q1 |
| Immunology | 52 / 243 | 78th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1991–present, best quartile Q1, CiteScore 8.7.
Inflammopharmacology is Q1 in Pharmacology (medical) (rank 31 of 278), Q1 in Pharmacology (rank 50 of 328) and Q1 in Immunology (rank 52 of 243), by CiteScore 2025.
Inflammopharmacology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.7, which places it in quartile Q1 at the 89th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.373, quartile Q1, with an H-index of 81.
The publisher lists an article processing charge of about US$4,990 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Inflammopharmacology is published by Springer Science and Business Media Deutschland GmbH. Its print ISSN is 0925-4692 and its online ISSN is 1568-5608.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Inflammopharmacology has an h-index of 92 and a 2-year mean of 5.17 citations per paper (OpenAlex). Its Scopus CiteScore is 8.7, quartile Q1. On 2-year citations it ranks #23 of 271 Scopus journals in Pharmacology (medical).
Inflammopharmacology published 458 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2026), authors are most often from India (31.9%), Egypt (14.2%) and Pakistan (11.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 28 retracted papers are recorded (9.2 per 1,000 papers). The Problematic Paper Screener flags 3 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.